Eli Lilly’s stock plunges as Mounjaro, Zepbound sales miss by wide margins




Eli Lilly’s stock heads for biggest selloff in 24 years after sales of anti-obesity drugs Mounjaro and Zepbound came up well short of forecasts.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

  ⁄  three  =  3